Benefits of Using High-Functionality Excipients in a Continuous Manufacturing Process

April 10, 2019

As pharmaceutical companies move increasingly toward changing production methods from batch to continuous processing, there is a need to re-evaluate the types and formulations of the excipients used. Within a continuous process, conventional monofunctional excipients must be added through individual feeders, potentially creating multiple sources of variability. In contrast, a single high-functionality co-processed excipient requires only one feeder, thus enhancing product performance while minimizing variability. 

Spotlight

Asklepios

Asklepios is a privately held hospital group founded by Dr. gr. Broermann in 1984. It is now operating more than 100 hospitals mainly based in Germany and generating a revenue of 2.3 billion €, making it the largest hospital group in Europe. With its Asklepios Future Hospital Program it initiated an R&D innovation program that is one of it's kind, partnering with 27 industry partners including Intel, Microsoft, Siemens and SAP.

OTHER WHITEPAPERS
news image

Ultrasafe film Ultra-high barrier Product stability Patient safety

whitePaper | December 22, 2022

Every viable pharmaceutical packaging system must comprise materials proven to protect its contents against moisture and other atmospheric variables, and be safe for use with the specified dosage form and the route of administration1

Read More
news image

Pharma R&D Annual Review 2022

whitePaper | May 5, 2022

welcome to pharmaprojects'2022 review of trends in pharmaceutical R&D for 30 year now, I've been taking an anual look at the evloution of pharma

Read More
news image

Protein fingerprints pave the way for microarray comparison

whitePaper | June 9, 2022

Anaxomics has developed a novel method of analysis for microarray data based on the generation and subsequent comparison of 2D fingerprints for each sample. Microarray results are incorporated into a protein interaction network and embedded with all sorts of biological and medical data.

Read More
news image

Demystifying content marketing for the pharma industry

whitePaper | November 10, 2022

We know people don’t like to be sold to. And in the so-called ‘attention economy’, it is more important than ever that your business can utilise meaningful marketing and advertising practices to engage with your customers and secure their attention.

Read More
news image

Securing the modern pharmaceutical supply chain

whitePaper | April 22, 2022

Members of the Health-ISAC community have produced a security framework for the pharmaceutical supply chain comprising this CISO guide.

Read More
news image

Market Access Trends in the US, Europe, and Emerging Markets

whitePaper | November 14, 2022

Rising drug spending and increased desire for expenditure controls are consistent themes across the US, Europe, and emerging markets.

Read More

Spotlight

Asklepios

Asklepios is a privately held hospital group founded by Dr. gr. Broermann in 1984. It is now operating more than 100 hospitals mainly based in Germany and generating a revenue of 2.3 billion €, making it the largest hospital group in Europe. With its Asklepios Future Hospital Program it initiated an R&D innovation program that is one of it's kind, partnering with 27 industry partners including Intel, Microsoft, Siemens and SAP.

Events